<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="320580">
  <stage>Registered</stage>
  <submitdate>23/08/2010</submitdate>
  <approvaldate>23/11/2010</approvaldate>
  <actrnumber>ACTRN12610001024033</actrnumber>
  <trial_identification>
    <studytitle>Safety and Benefits of A Tablet Combining Losartan and Hydrochlorothiazide in Hypertensive Patients with Diabetes</studytitle>
    <scientifictitle>Safety and Benefits of A Tablet Combining Losartan and Hydrochlorothiazide in Hypertensive Patients with Diabetes</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>Cochrane Renal Group (CRG) CRG010900155</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>diabetic patients with hypertension</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>The study was performed by daily oral administration of losartan/hydrochlorothiazide combined tablet for 3 months.
The doses of losartan/hydrochlorothiazide were fixed throughout the study at 50mg/12.5mg/day. 
This study was designed as a cross-over study. We did not have the washout period.</interventions>
    <comparator>The study was performed by daily oral administration of losartan combined tablet for 3 months.
The doses of losartan were fixed throughout the study at 50mg/day. 
This study was designed as a cross-over study. We did not have the washout period.</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Serum levels of creatinine (Cr), cystatin C, potassium (K), uric acid (UA), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), glucose, and glycoalbumin (GA), and plasma levels of brain natriuric peptide (BNP), active renin concentrations (ARC), and aldosterone (PAC) were measured in venous blood samples, drawn in the morning after an overnight fast on the same days as the cardio-ankle vascular index (CAVI), augmentation index (AI), and blood pressure (BP) measurements were taken. Timepoints: 3 and 6 months</outcome>
      <timepoint>at 3 and 6 months from baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>None</outcome>
      <timepoint>None</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diabetic patients who had untreated hypertension or uncontrollable hypertension treated with medications except for renin-angiotensin system (RAS) inhibitors.</inclusivecriteria>
    <inclusiveminage>20</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Patients with serious refractory hypertension defined as more than 120 mmHg in diastolic BP, history of acute myocardial infarction, stroke, or any other cardiovascular events within 6 months, heart failure with New York Heart Association (NYHA) grade III, or grade IV, history of gout or hyperuricemia at the beginning of this study, kidney dysfunction defined as a serum creatinine level of more than 2 mg/dl, liver dysfunction defined as a serum transaminase level more than 3 times higher than normal, bilateral renal artery stenosis, secondary, or malignant hypertension, polycystic kidney disease, congenital kidney deformities, solitary kidney, pregnancy or probable pregnancy, history of allergy to the medication in this study, or those considered inappropriate.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Japan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>Keio University School of Medicine</primarysponsorname>
    <primarysponsoraddress>35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan</primarysponsoraddress>
    <primarysponsorcountry>Japan</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>Keio University School of Medicine</fundingname>
      <fundingaddress>35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan</fundingaddress>
      <fundingcountry>Japan</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Keio University School of Medicine</sponsorname>
      <sponsoraddress>35 Shinanomachi, Shinjuku, Tokyo, 160-8582, Japan</sponsoraddress>
      <sponsorcountry>Japan</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>A/Prof, Atsuhiro, Ichihara</name>
      <address>, Endocrinology &amp; Anti-Aging Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JAPAN</address>
      <phone>+81-3-5363-3796</phone>
      <fax />
      <email>atzichi@sc.itc.keio.ac.jp</email>
      <country>Japan</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>A/Prof, Atsuhiro, Ichihara</name>
      <address>Associate Professor, Endocrinology &amp; Anti-Aging Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, JAPAN</address>
      <phone>+81-3-5363-3796</phone>
      <fax />
      <email>atzichi@sc.itc.keio.ac.jp</email>
      <country>Japan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>